- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07596446
FEMART-1 Pilot Study (FEMART-1)
The FEMART-1 Pilot Study is focused on evaluating the feasibility, safety, and procedural timing of prehospital femoral arterial sheath placement in patients with non-traumatic out-of-hospital cardiac arrest (OHCA), both during ongoing cardiopulmonary resuscitation and after return of spontaneous circulation (ROSC).
The primary objective of the study is to enable invasive arterial blood pressure monitoring for targeted and continuous hemodynamic management using vasopressor therapy in the prehospital setting. The study evaluates the feasibility, safety, and procedural performance of invasive arterial monitoring with the aim of improving assessment of the patient's hemodynamic status and enabling more accurate titration of vasopressor support. This approach may reduce episodes of hypotension and decrease the risk of recurrent cardiac arrest while allowing safer transport to specialized cardiac arrest centers.
Femoral arterial access enables more precise monitoring of perfusion pressure, targeted vasopressor titration, and early recognition of impending circulatory collapse. The intervention may contribute to improved early organ perfusion and could be associated with more favorable neurological and overall clinical outcomes after cardiac arrest. In accordance with the ERC Guidelines 2025, which emphasize active hemodynamic optimization after ROSC and acknowledge the potential role of invasive arterial pressure monitoring during ongoing resuscitation, the study evaluates not only feasibility, safety, and procedural timing, but also the potential clinical benefit of continuous hemodynamic-guided management in the prehospital phase, including (1) early identification of hypotension, (2) targeted vasopressor administration, and (3) prevention of re-arrest.
The study is conducted by the Prague Air Rescue Service Kryštof 01 (Prague Emergency Medical Services) in collaboration with the Central Bohemian Emergency Medical Service, the Second Department of Internal Medicine - Cardiology and Angiology of the General University Hospital in Prague and First Faculty of Medicine, Charles University, and the Department of Anesthesiology, Resuscitation and Intensive Care Medicine of the General University Hospital in Prague and First Faculty of Medicine, Charles University.
FEMART-1 is designed as a prospective pilot study without external funding.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Jan Spicak, MD
- Numer telefonu: 00420776155836
- E-mail: jan.spicak@zzshmp.cz
Kopia zapasowa kontaktu do badania
- Nazwa: Silvie Trhlikova, MD, PhD
- Numer telefonu: MD 00420607610869
- E-mail: silvie.trhlikova@zzshmp.cz
Lokalizacje studiów
-
-
-
Prague, Czechy, 10100
- Rekrutacyjny
- EMS Prague
-
Kontakt:
- Jan Spicak, MD
- Numer telefonu: +420776155836
- E-mail: jan.spicak@zzshmp.cz
-
Kontakt:
- Silvie Trhlikova, MD PhD
- Numer telefonu: +420607610869
- E-mail: silvie.trhlikova@zzshmp.cz
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
* Non-traumatic out-of-hospital cardiac arrest (OHCA).
Patients meeting criteria for one of the following clinical scenarios:
Group A - ECPR-like group:
- Refractory cardiac arrest, including cardiac arrest occurring in the presence of the EMS crew.
- Age 18-70 years.
- Effective bystander cardiopulmonary resuscitation.
- Initial rhythm of ventricular fibrillation (VF), pulseless ventricular tachycardia (pVT), or pulseless electrical activity (PEA).
Group B - post-ROSC group:
- Return of spontaneous circulation (ROSC) after non-traumatic OHCA.
- Age 18-70 years.
Exclusion Criteria:
- Trauma as the probable primary cause of cardiac arrest.
Known severe comorbidity, including:
- terminal stage of incurable disease (advanced malignancy, advanced dementia, terminal pulmonary disease, terminal heart failure, or palliative care status),
- established do-not-resuscitate (DNR) status,
- severe pre-existing neurological disability (CPC 3 or CPC 4),
- known severe peripheral arterial disease or known occlusion of lower limb arteries,
- suspected pulmonary embolism with indication for thrombolytic therapy,
- known severe hematological disease associated with severe thrombocytopenia,
- morbid obesity.
- Known or suspected pregnancy.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Prehospital Femoral Arterial Sheath Insertion
Patients receive standard advanced prehospital resuscitation and post-resuscitation care including ultrasound-guided femoral arterial sheath insertion for invasive blood pressure monitoring and potential facilitation of subsequent VA-ECMO cannulation if clinically indicated.
|
Ultrasound-guided placement of a femoral arterial sheath in the prehospital setting during ongoing cardiopulmonary resuscitation or after return of spontaneous circulation.
The procedure is performed to enable invasive arterial blood pressure monitoring, optimization of hemodynamic management during ongoing cardiopulmonary resuscitation or post-resuscitation care, prevention of re-arrest, and to facilitate rapid transition to potential VA-ECMO cannulation if clinically indicated.
Inne nazwy:
|
|
Brak interwencji: Standard Prehospital Care
Patients receive standard advanced prehospital resuscitation and post-resuscitation care without prehospital femoral arterial sheath insertion.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Patients With Successful and Functional Invasive Arterial Blood Pressure Monitoring
Ramy czasowe: During prehospital care until hospital arrival
|
Feasibility of prehospital femoral arterial sheath placement expressed as the percentage of patients with successfully established and functional invasive arterial blood pressure monitoring among patients in whom prehospital femoral arterial sheath placement was attempted following a clinical decision to perform the procedure.
|
During prehospital care until hospital arrival
|
|
Percentage of Patients With Major Procedure-Related Complications
Ramy czasowe: From sheath insertion until hospital admission
|
Safety of prehospital femoral arterial sheath placement expressed as the percentage of patients with major procedure-related complications among patients in whom prehospital femoral arterial sheath placement was attempted following a clinical decision to perform the procedure.
Major complications include clinically significant bleeding, vascular injury, distal limb ischemia, or sheath-related complications requiring therapeutic intervention.
|
From sheath insertion until hospital admission
|
|
Procedural Time Characteristics of Prehospital Femoral Arterial Sheath Placement
Ramy czasowe: During prehospital care until hospital arrival
|
Assessment of procedural time characteristics of prehospital femoral arterial sheath placement among patients in whom the procedure was attempted following a clinical decision to perform the intervention.
Time intervals are assessed using predefined procedural time points recorded during the intervention.
|
During prehospital care until hospital arrival
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Use of Vasopressor or Inotropic Therapy in the Prehospital Setting
Ramy czasowe: During prehospital care until hospital arrival
|
Comparison of the number and proportion of patients receiving vasopressor or inotropic therapy during prehospital care.
|
During prehospital care until hospital arrival
|
|
Recognition of Impending Hemodynamic Collapse After ROSC
Ramy czasowe: During prehospital care until hospital arrival
|
Comparison of the number and proportion of patients with return of spontaneous circulation who develop hypotension (MAP below 50 mmHg) associated with re-initiation of cardiopulmonary resuscitation, initiation of vasopressor therapy, or escalation of ongoing vasopressor therapy during prehospital care.
|
During prehospital care until hospital arrival
|
|
Prehospital Re-arrest Rate
Ramy czasowe: During prehospital care until hospital arrival
|
Comparison of the number and proportion of patients requiring defibrillation or manual/mechanical cardiopulmonary resuscitation after previously achieved return of spontaneous circulation during prehospital care.
|
During prehospital care until hospital arrival
|
|
In-Hospital Re-arrest Within 20 Minutes After Handover
Ramy czasowe: Within 20 minutes after hospital admission
|
Comparison of the number and proportion of patients transferred to the receiving hospital with return of spontaneous circulation who subsequently require defibrillation or manual/mechanical cardiopulmonary resuscitation within 20 minutes after hospital handover.
|
Within 20 minutes after hospital admission
|
|
Adequate Mean Arterial Pressure at Hospital Handover
Ramy czasowe: At hospital admission
|
Comparison of the number and proportion of patients with mean arterial pressure above 60 mmHg at hospital handover.
|
At hospital admission
|
|
Blood Lactate Level at Hospital Admission
Ramy czasowe: At hospital admission
|
Comparison of median and mean lactate levels measured at hospital admission.
|
At hospital admission
|
|
Heart Rate at Hospital Admission
Ramy czasowe: At hospital admission
|
Comparison of median and mean heart rate measured at hospital admission.
|
At hospital admission
|
|
Survival and Neurological Clinical Outcomes
Ramy czasowe: Through hospital discharge (up to 30 days) and at 30 days after the index event
|
Comparison of the number and percentage of patients surviving to hospital discharge, surviving with favorable neurological outcome defined as Cerebral Performance Category (CPC) 1-2 at hospital discharge, and surviving 30 days after the index event.
|
Through hospital discharge (up to 30 days) and at 30 days after the index event
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Jan Spicak, MD, Prague Emergency Medical Services
Publikacje i pomocne linki
Publikacje ogólne
- Ule J, Huppe T, Thiel J, Berwanger U, Schlechtriemen T, Conrad D, Merscher B. Implementing prehospital invasive arterial blood pressure monitoring in critically ill patients-a prospective observational first year analysis. Scand J Trauma Resusc Emerg Med. 2025 Sep 2;33(1):145. doi: 10.1186/s13049-025-01461-9.
- Butterfield ED, Price J, Bonsano M, Lachowycz K, Starr Z, Edmunds C, Barratt J, Major R, Rees P, Barnard EBG. Prehospital invasive arterial blood pressure monitoring in critically ill patients attended by a UK helicopter emergency medical service- a retrospective observational review of practice. Scand J Trauma Resusc Emerg Med. 2024 Mar 12;32(1):20. doi: 10.1186/s13049-024-01193-2.
- Wildner G, Pauker N, Archan S, Gemes G, Rigaud M, Pocivalnik M, Prause G. Arterial line in prehospital emergency settings - A feasibility study in four physician-staffed emergency medical systems. Resuscitation. 2011 Sep;82(9):1198-201. doi: 10.1016/j.resuscitation.2011.05.002. Epub 2011 May 11.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- ZZSHMP_001_2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .